MCID: SPN052
MIFTS: 54

Spondyloarthropathy

Categories: Bone diseases, Genetic diseases, Muscle diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Spondyloarthropathy

MalaCards integrated aliases for Spondyloarthropathy:

Name: Spondyloarthropathy 12 15 39 17
Spondylarthropathies 43 71
Spondyloarthropathy, Susceptibility to 29
Spondarthropathy 12
Spondylarthrosis 12
Spondylarthritis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:1123
MeSH 43 D025242
SNOMED-CT 67 372109003
UMLS 71 C0949690 C0949691

Summaries for Spondyloarthropathy

MalaCards based summary : Spondyloarthropathy, also known as spondylarthropathies, is related to juvenile spondyloarthropathy and spondyloarthropathy 1, and has symptoms including sciatica An important gene associated with Spondyloarthropathy is SPDA2 (Spondyloarthropathy, Susceptibility To, 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pamidronate and Etoricoxib have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and skin, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Spondyloarthropathy or spondyloarthrosis refers to any joint disease of the vertebral column. As such,... more...

Related Diseases for Spondyloarthropathy

Diseases in the Spondyloarthropathy family:

Spondyloarthropathy 1 Spondyloarthropathy 2
Spondyloarthropathy 3 Juvenile Spondyloarthropathy

Diseases related to Spondyloarthropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 809)
# Related Disease Score Top Affiliating Genes
1 juvenile spondyloarthropathy 35.0 LTA IL2
2 spondyloarthropathy 1 34.9 TNFSF11 TNF MMP3 IL17A HLA-B
3 spondylarthropathy 32.7 TNF SPDA3 LTA
4 reactive arthritis 31.7 TNF IL6 IL1B IL17A IL10 IFNG
5 iridocyclitis 31.6 TNF IL6 IL17A IL10 HLA-B
6 ankylosis 31.5 TNFSF11 TNF IL17A
7 spondylitis 31.5 TNFSF11 TNF LTA IL6 IL23A IL17A
8 synovitis 31.4 TNFSF11 TNF MMP3 IL6 IL1B IL17A
9 juvenile arthritis 31.3 IL6 IL10 HLA-A
10 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.3 IL17A IL10 IFNG
11 crohn's colitis 31.3 TNF IL2 IL1B IFNG
12 arthropathy 31.2 TNFSF11 TNF MMP3 LTA IL6 IL1B
13 aortitis 31.2 TNF IL6 IL1B IL17A
14 urethritis 31.1 TNF IL6 IL1B
15 iritis 31.1 TNF IL6 IL17A HLA-B
16 fibromyalgia 31.1 TNF IL6 IL1B IL10
17 carpal tunnel syndrome 31.0 IL6 IL2 IL1B
18 bone resorption disease 31.0 TNFSF11 TNF IL6 IL1B
19 familial mediterranean fever 31.0 TNF IL6 IL1B IL17A IL10 HLA-A
20 vasculitis 31.0 TNF IL6 IL17A IL10 HLA-B
21 spinal disease 31.0 TNF IL6 IL1B IL17A
22 temporal arteritis 31.0 TNF IL6 IL1B IL17A IFNG
23 chlamydia 31.0 TNF IL6 IL4 IL1B IL17A IL10
24 tendinitis 31.0 TNF MMP3 IL6 IL1B
25 crohn's disease 30.9 TNF IL6 IL4 IL23A IL2 IL1B
26 hidradenitis suppurativa 30.9 TNF LTA IL1B IL17A IFNG
27 hidradenitis 30.9 TNF LTA IL1B IL17A IFNG
28 osteoarthritis 30.9 TNFSF11 TNF MMP3 IL6 IL1B IL17A
29 brucellosis 30.9 TNF IL6 IL4 IL2 IL17A IL10
30 uveitis 30.9 TNF LTA IL6 IL4 IL2 IL1B
31 juvenile rheumatoid arthritis 30.8 TNF MMP3 LTA IL6 IL2 IL1B
32 dysentery 30.8 TNF IL6 IL1B IL10
33 thyroiditis 30.8 TNF IL6 IL4 IL2 IL10
34 fasciitis 30.8 TNF LTA IL6 IL2 IFNG
35 diarrhea 30.8 TNF IL6 IL2 IL1B IL10 IFNG
36 exanthem 30.8 TNF IL6 IL2 IL1B IL10 IFNG
37 radiculopathy 30.8 IL6 IL17A IL10
38 ulcerative colitis 30.7 TNF IL6 IL4 IL23A IL2 IL1B
39 mixed connective tissue disease 30.7 TNF IL6 IL10 IFNG
40 bacterial infectious disease 30.7 TNF IL6 IL1B IL17A IL10 IFNG
41 conjunctivitis 30.7 TNF IL6 IL4 IL2 IL10 IFNG
42 acute cystitis 30.7 TNF IL6 IL1B IL10
43 adult-onset still's disease 30.6 TNF IL6 IL1B
44 osteomyelitis 30.6 TNFSF11 TNF IL6 IL4 IL1B IL10
45 relapsing polychondritis 30.6 IL6 IL2 IL17A IL10 IFNG
46 proliferative glomerulonephritis 30.6 IL6 IL4 IFNG
47 chronic recurrent multifocal osteomyelitis 30.6 TNFSF11 TNF IL6 IL1B
48 neutropenia 30.6 TNF IL6 IL2 IL1B IL10 IFNG
49 periodontitis, chronic 30.5 TNFSF11 IL6 IL1B
50 septic arthritis 30.5 TNF MMP3 IL6 IL1B IFNG

Graphical network of the top 20 diseases related to Spondyloarthropathy:



Diseases related to Spondyloarthropathy

Symptoms & Phenotypes for Spondyloarthropathy

UMLS symptoms related to Spondyloarthropathy:


sciatica

GenomeRNAi Phenotypes related to Spondyloarthropathy according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 9.72 HLA-A HLA-B HLA-C
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 9.72 HLA-A HLA-B HLA-C
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 9.72 HLA-C
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 9.72 HLA-A HLA-B HLA-C
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 9.72 HLA-A HLA-B HLA-C
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 9.72 HLA-A HLA-B HLA-C
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 9.72 HLA-C
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 9.72 HLA-A HLA-B HLA-C
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 9.72 HLA-A HLA-B HLA-C
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.72 HLA-C
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.72 HLA-C

MGI Mouse Phenotypes related to Spondyloarthropathy:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 HLA-A IFNG IL10 IL17A IL17F IL1B
2 immune system MP:0005387 10.28 HLA-A IFNG IL10 IL17A IL17F IL1B
3 homeostasis/metabolism MP:0005376 10.25 IFNG IL10 IL17A IL1B IL2 IL22RA1
4 endocrine/exocrine gland MP:0005379 10.18 HLA-A IFNG IL10 IL17A IL2 IL4
5 mortality/aging MP:0010768 10.17 HLA-A IFNG IL10 IL17A IL17F IL1B
6 digestive/alimentary MP:0005381 10.15 IFNG IL10 IL17A IL17F IL2 IL23A
7 craniofacial MP:0005382 10.11 IFNG IL10 IL17A IL17F IL1B IL4
8 integument MP:0010771 10.07 IFNG IL10 IL17A IL1B IL22RA1 IL23A
9 neoplasm MP:0002006 9.86 IFNG IL10 IL1B IL2 IL23A IL6
10 no phenotypic analysis MP:0003012 9.81 HLA-A IFNG IL10 IL17A IL2 IL23A
11 respiratory system MP:0005388 9.65 IFNG IL10 IL17A IL17F IL2 IL4
12 skeleton MP:0005390 9.36 IFNG IL10 IL17A IL17F IL1B IL4

Drugs & Therapeutics for Spondyloarthropathy

Drugs for Spondyloarthropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pamidronate Approved Phase 4 40391-99-9 4674
2
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
8
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
9
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
10
Certolizumab pegol Approved Phase 4 428863-50-7
11
Abatacept Approved Phase 4 332348-12-6 10237
12
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
13
Hydroxychloroquine Approved Phase 4 118-42-3 3652
14
Infliximab Approved Phase 4 170277-31-3
15
Etanercept Approved, Investigational Phase 4 185243-69-0
16 Cyclooxygenase 2 Inhibitors Phase 4
17 Cyclooxygenase Inhibitors Phase 4
18 triamcinolone acetonide Phase 4
19 Triamcinolone diacetate Phase 4
20 Triamcinolone hexacetonide Phase 4
21 Pharmaceutical Solutions Phase 4
22 Narcotics Phase 4
23 Anesthetics Phase 4
24 Analgesics, Opioid Phase 4
25 Anesthetics, General Phase 4
26 Anesthetics, Local Phase 4
27 Anesthetics, Intravenous Phase 4
28 Sodium Channel Blockers Phase 4
29 Anti-Arrhythmia Agents Phase 4
30 Diuretics, Potassium Sparing Phase 4
31 Tocolytic Agents Phase 4
32 Vaccines Phase 4
33 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
34 Anti-Infective Agents Phase 4
35 Antiprotozoal Agents Phase 4
36 Antiparasitic Agents Phase 4
37 Antimalarials Phase 4
38 Immunoglobulins Phase 4
39 Antibodies Phase 4
40 Antibodies, Monoclonal Phase 4
41 Analgesics, Non-Narcotic Phase 4
42 Analgesics Phase 4
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4
44 Gastrointestinal Agents Phase 4
45 Antibodies, Anti-Idiotypic Phase 4
46
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
47
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
48
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
49
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
50 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1

Interventional clinical trials:

(show top 50) (show all 240)
# Name Status NCT ID Phase Drugs
1 Can New Imaging- and Bio-markers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Spondyloarthritis Patients Receiving Adalimumab Unknown status NCT00477893 Phase 4 Adalimumab;Placebo
2 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
3 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
4 Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh Unknown status NCT03504072 Phase 4 Tofacitinib 5 mg,;Etanercept
5 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
6 A Prospective Study of the Use of the Madrid Ultrasound Scoring System in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis Completed NCT02960035 Phase 4 50mg etanercept;25mg etanercept;placebo
7 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding Completed NCT03190603 Phase 4 Celecoxib
8 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
9 A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients With Refractory Heel Enthesitis in Spondylarthropathy Completed NCT00420303 Phase 4 Etanercept
10 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
11 Influence of Epidural Analgesia in Elective Laparoscopic Colorectal Resections Completed NCT00512395 Phase 4 epidural analgesia (Duracain/Fentanyl/Naropin)
12 A Multi Centre, Double Blind, Placebo-controlled Study to Evaluate the Non Steroidal Anti-inflamatory Drugs (NSAIDS) Sparing Effect of Etanercept in Adult Subjects With Axial Involvement of Spondyloarthritis Completed NCT01298531 Phase 4 etanercept;etanercept;placebo
13 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
14 Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW) Completed NCT03020992 Phase 4 Certolizumab Pegol
15 Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar® Completed NCT00828997 Phase 4
16 Ultrasound Guided Epidural Block in Axial SPA Patient With Limited Spine Mobility: a Prospective Pilot Randomized Controlled Trial Completed NCT04143165 Phase 4 Epidural block with lidocaine and triamcinilone
17 Adalimumab in Axial Spondyloarthritis. An Investigation of Whole-body MRI, MRI of Sacroiliac Joints and Spine and Soluble Biomarkers of Joint Inflammation and Damage. Completed NCT01029847 Phase 4 Adalimumab;Placebo
18 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study Completed NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
19 Effect of Continuous Administration of Different Therapeutic Dosages of Indomethacin and Etoricoxib in the Management of Axial Spondyloarthritis: A Randomized Controlled Trial Completed NCT03582332 Phase 4 Indomethacin SR, 75 Mg Oral Capsule, Extended Release;Indomethacin 25 Mg Oral Capsule;Etoricoxib 90 mg;Etoricoxib 60 mg
20 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
21 Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu® Completed NCT02364479 Phase 4 50mg Yisaipu;25mg etanercept;Placebo
22 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
23 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Recruiting NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
24 Abatacept Bone Effects in Psoriatic Arthritis With Bone Biomarkers - ABEPSA _ BB Recruiting NCT04106804 Phase 4 Abatacept 125 MG/ML
25 Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis Recruiting NCT03445845 Phase 4 Secukinumab;TNF blocker
26 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Active, not recruiting NCT03762824 Phase 4
27 A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis Active, not recruiting NCT03253796 Phase 4
28 Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Not yet recruiting NCT04077957 Phase 4 Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept (50mg per week, for 4 weeks);Etanercept (50mg per week, for 2 weeks);Etanercept (50mg per week)
29 Study of Peripheral Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab Terminated NCT00686894 Phase 4 Infliximab
30 STRIKE - Treating Patients With Early Axial Spondyloarthritis to Target - a 1 Year Randomized Controlled Study Taking an Intense Treatment Approach Versus Routine Treatment Terminated NCT02897115 Phase 4
31 Discontinuation of TNF-alpha Inhibitors in Spondylarthritis Patients With Low Disease Activity, and Re-initiation of Therapy if Disease Flares Terminated NCT00726804 Phase 4 Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)
32 Comparative Analysis of Two Therapeutic Strategies: "Early Switch" Versus "Therapeutic Intensification" in Patients With Spondyloarthritis Treated With Anti-tnf Biologics, in Case of Secondary Treatment Failure Suspicion. Terminated NCT01971918 Phase 4
33 Methotrexate in the Treatment of Axial Spondyloarthritis. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study. Withdrawn NCT00298012 Phase 4 Methotrexate
34 Efficacy of Adalimumab (Humira®) in Spondyloarthritis Related to Crohn's Disease Withdrawn NCT00972218 Phase 4
35 Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS Unknown status NCT02809781 Phase 2, Phase 3 Etanercept
36 Threecenter Placebo Controlled Three Arm Trial in Patients With Active Ankylosing Spondylitis With Prednisolone Unknown status NCT00244166 Phase 2, Phase 3 prednisolone
37 A Prospective Double Blind Placebo Controlled Trial of Combination Disease Modifying Antirheumatic Drugs (DMARDs) vs Monotherapy (Sulfasalazine) in Patients With Inflammatory Low Backache in Early Seronegative Spondylarthropathy Completed NCT01040195 Phase 3 Methotrexate, Hydroxychloroquine;Placebo
38 Mechanism of Action Study of Anti-IL17 Treatment in Spondyloarthritis: Impact on Cellular and Molecular Pathways of Synovial Inflammation and Tissue Remodeling Completed NCT03358134 Phase 3 Secukinumab
39 Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis Completed NCT01087762 Phase 3
40 A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS Completed NCT01583374 Phase 3 Apremilast tablet 20 mg;Apremilast tablet 30 mg BID;Placebo
41 Efficacy, Safety, and Tolerability of Infliximab (Remicade; Schering-Plough) in Juvenile Spondyloarthropathies: a Three-Month, Randomized, Double-Blind, Placebo-Controlled Trial and 52-Week Open Extension. Completed NCT00591201 Phase 2, Phase 3 infliximab;Placebo
42 A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis Completed NCT02757352 Phase 3 Ixekizumab;Placebo
43 A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis Completed NCT02696798 Phase 3 Ixekizumab;Placebo
44 A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo Completed NCT02505542 Phase 3
45 A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis Completed NCT02696785 Phase 3 Ixekizumab;Placebo;Adalimumab
46 Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria Completed NCT01426815 Phase 3 Placebo;Golimumab
47 Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial Completed NCT00844805 Phase 3 Infliximab;Placebo;Naproxen
48 A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes, to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis Completed NCT02896127 Phase 3 Secukinumab;Placebo
49 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of KHK4827 in Subjects With Axial Spondyloarthritis Completed NCT02985983 Phase 3 KHK4827;Placebo
50 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Peripheral Spondyloarthritis Completed NCT01064856 Phase 3

Search NIH Clinical Center for Spondyloarthropathy

Cochrane evidence based reviews: spondylarthropathies

Genetic Tests for Spondyloarthropathy

Genetic tests related to Spondyloarthropathy:

# Genetic test Affiliating Genes
1 Spondyloarthropathy, Susceptibility to 29

Anatomical Context for Spondyloarthropathy

MalaCards organs/tissues related to Spondyloarthropathy:

40
Bone, T Cells, Skin, Testes, Eye, Colon, Breast

Publications for Spondyloarthropathy

Articles related to Spondyloarthropathy:

(show top 50) (show all 1959)
# Title Authors PMID Year
1
Refractive surgery for the patient with autoimmune diseases. 61
32412958 2020
2
Metabolomics analysis revealed significantly higher synovial Phe/Tyr ratio in reactive arthritis and undifferentiated spondyloarthropathy. 61
31641751 2020
3
New onset of axial spondyloarthropathy in patients treated with isotretinoin for acne vulgaris: incidence, follow-up, and MRI findings. 61
32034553 2020
4
Modulation of Natural HLA-B*27:05 Ligandome by Ankylosing Spondylitis-associated Endoplasmic Reticulum Aminopeptidase 2 (ERAP2). 61
32265295 2020
5
Calcaneal quantitative ultrasound has a role in out ruling low bone mineral density in axial spondyloarthropathy. 61
31953568 2020
6
The immunobiology of mTOR in autoimmunity. 61
31831256 2020
7
Psoriatic Arthritis and Diabetes Mellitus: A Narrative Review. 61
32306243 2020
8
Factors Predictive of Remission of Chronic Anterior Uveitis. 61
31932091 2020
9
Pharmacological treatment for managing bone health in axial spondyloarthropathy: systematic review and meta-analysis. 61
32556472 2020
10
Diagnostic performance of plain radiography for sacroiliitis in patients with suspected axial spondyloarthritis: a systematic review and meta-analysis. 61
32536262 2020
11
Using genetics to prioritize diagnoses for rheumatology outpatients with inflammatory arthritis. 61
32461333 2020
12
Hidradenitis Suppurativa: An Update on Epidemiology, Phenotypes, Diagnosis, Pathogenesis, Comorbidities and Quality of Life. 61
32460374 2020
13
Ultrasonographic evaluation of Achilles tendon: Is there any difference between ankylosing spondylitis, non-radiographic axial spondyloarthropathy and controls? 61
31985181 2020
14
Revision Total Hip Arthroplasty in Patients With Ankylosing Spondylitis: Long-Term Results. 61
32418748 2020
15
Concurrent Joint Hypermobility Syndrome and Spondyloarthropathy: A New Spondyloarthropathy Subgroup With a Less Severe Disease Phenotype? 61
30601197 2020
16
Qualitative and quantitative assessment of sacroiliitis in axial spondyloarthropathy: can a single T2-weighted dixon sequence replace the standard protocol? 61
31973943 2020
17
T-cell receptor immunosequencing reveals altered repertoire diversity and disease-associated clonal expansions in ankylosing spondylitis patients. 61
32162785 2020
18
Non-infectious thoracic discitis: A diagnostic and management dilemma. A report of two cases with review of the literature. 61
31931336 2020
19
Interleukin-23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy. 61
31957051 2020
20
A rare case of spondyloarthropathy: Iatrogenic hypoparathyroidism. 61
32318681 2020
21
Pattern of uveitis in a tertiary eye care center of central India: Results of a prospective patient database over a period of two years. 61
32057007 2020
22
Measuring bone density in axial spondyloarthropathy: Time to turn things on their side? 61
31909570 2020
23
Risk factors for in-hospital mortality after spine surgery: a matched case-control study using a multicenter database. 61
31669616 2020
24
Performance of the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus in Asian patients: a single-centre retrospective cohort study in Korea. 61
32083550 2020
25
Similarities between pediatric FMF patients with sacroiliitis and pediatric juvenile spondyloarthropathy patients with sacroiliitis: a preliminary study. 61
32009575 2020
26
Multimorbidity in Axial Spondyloarthropathy and Its Association with Disease Outcomes: Results from the Ankylosing Spondylitis Registry of Ireland Cohort. 61
31092715 2020
27
Value of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Spondyloarthropathy-Related Aortitis. 61
32028301 2020
28
Clinical manifestations, disease activity and disease burden of radiographic versus non-radiographic axial spondyloarthritis over 5 years of follow-up in the DESIR cohort. 61
31784451 2020
29
Surgical Stabilization of a Cervical Fracture in a Patient with Ankylosing Spondylitis in the Sitting Position. 61
31966941 2020
30
The important role of central sensitization in chronic musculoskeletal pain seen in different rheumatic diseases. 61
31446538 2020
31
Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study. 61
30048391 2020
32
Epidemiological survey and risk factor analysis of dialysis-related amyloidosis including destructive spondyloarthropathy, dialysis amyloid arthropathy, and carpal tunnel syndrome. 61
31414282 2020
33
Association Study between Psoriatic Arthritis and Killer Immunoglobulin-Like Receptor (KIR) Genes: A Meta-Analysis. 61
31957514 2020
34
Endobronchial ultrasound-guided transbronchial needle aspirate for diagnosis of anaplastic large cell lymphoma of unusual presentation: A case report. 61
32140403 2020
35
Dystrophic calcification and heterotopic ossification in fibrocartilaginous tissues of the spine in diffuse idiopathic skeletal hyperostosis (DISH). 61
32257530 2020
36
Patients with enthesitis related arthritis show similar monocyte function pattern as seen in adult axial spondyloarthropathy. 61
31941549 2020
37
Early instauration granulomatous pneumonitis associated with use of etanercept in seronegative spondyloarthropathy: Case report. 61
32477861 2020
38
Pyoderma Gangrenosum as a Presenting Feature of Undifferentiated Spondyloarthropathy with Erosive Inflammatory Arthritis. 61
32274238 2020
39
Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five-Year Results From the DESIR Cohort. 61
30354022 2019
40
[Lower limb lymphedema: A rare manifestation of spondyloarthropathy]. 61
31279481 2019
41
The eye in spondyloarthritis✰. 61
31779847 2019
42
MR distribution of active inflammatory and chronic structural sacroiliac joint changes in axial spondyloarthropathy: Challenging conventional wisdom. 61
31252214 2019
43
The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases. 61
31207292 2019
44
Diagnostic efficacy of ultrasound detection of enthesitis in peripheral spondyloarthritis. 61
31663417 2019
45
[Biologics in rheumatology]. 61
31485714 2019
46
Long-Term Study about the Incidence of Epilepsy in Male Service Personnel from India: A Retrospective, Cohort Study. 61
31831976 2019
47
Cardiac Manifestations of Seronegative Spondyloarthropathy in a Human Leukocyte Antigen B27-Positive African American Woman: A Case Report With Literature Review. 61
31709378 2019
48
Expert's comment concerning Grand Rounds case entitled "Management of a pseudarthrosis with sagittal malalignment in a patient with ochronotic spondyloarthropathy" by Alkasem W, Boissiere L, Obeid I, Bourghli A (Eur Spine J; 2019: doi.org/10.1007/s00586-019-06020-2). 61
31286246 2019
49
Postcranial axial skeletal pathology in Commerson's dolphins Cephalorhynchus c. commersonii from Tierra del Fuego, Argentina. 61
31621651 2019
50
Management of a pseudarthrosis with sagittal malalignment in a patient with ochronotic spondyloarthropathy. 61
31175484 2019

Variations for Spondyloarthropathy

Expression for Spondyloarthropathy

Search GEO for disease gene expression data for Spondyloarthropathy.

Pathways for Spondyloarthropathy

Pathways related to Spondyloarthropathy according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 TNFSF11 TNF MMP3 LTA KIR3DL1 IL6
2
Show member pathways
13.93 TNFSF11 TNF LTA IL6 IL4 IL23A
3
Show member pathways
13.8 TNFSF11 TNF LTA IL6 IL4 IL23A
4
Show member pathways
13.66 TNF LTA IL6 IL4 IL23A IL22RA1
5
Show member pathways
13.54 TNFSF11 TNF LTA IL6 IL4 IL23A
6
Show member pathways
13.42 TNFSF11 TNF LTA IL6 IL4 IL23A
7
Show member pathways
13.12 TNF IL6 IL2 IL1B IL10 IFNG
8
Show member pathways
13.1 TNF IL6 IL4 IL2 HLA-C HLA-B
9
Show member pathways
13.01 TNF IL6 IL1B HLA-C HLA-B HLA-A
10
Show member pathways
12.97 TNF IL6 IL2 IL1B IFNG HLA-C
11 12.95 TNF LTA IL6 IL1B IFNG HLA-C
12
Show member pathways
12.83 TNF LTA IL6 IL4 IL2
13
Show member pathways
12.77 TNF LTA IL6 IL2 IL1B
14
Show member pathways
12.75 TNF IL6 IL4 IL2 IL1B IL17A
15
Show member pathways
12.72 TNF IL6 IL23A IL2 IL1B IL17F
16 12.71 TNFSF11 TNF IL4 IL2 IL1B IL17A
17
Show member pathways
12.71 TNF IL6 IL4 IL23A IL22RA1 IL2
18
Show member pathways
12.7 TNF IL4 IL2 IL10 IFNG
19
Show member pathways
12.66 TNF KIR3DL1 IL4 IL2 IFNG HLA-C
20
Show member pathways
12.66 TNFSF11 TNF MMP3 LTA IL6 IL4
21
Show member pathways
12.61 IL6 IL4 IL23A IL22RA1 IL2 IL10
22
Show member pathways
12.51 TNF LTA KIR3DL1 IL6 IL4 IL2
23 12.5 TNF LTA IL6 IL2 HLA-C HLA-B
24
Show member pathways
12.49 TNF LTA IL6 IL22RA1 IL2 IL10
25
Show member pathways
12.49 TNF IL6 IL4 IL2 IL1B IFNG
26
Show member pathways
12.48 TNF MMP3 IL6 IL4 IL1B IL17F
27 12.4 TNF IL6 IL23A IL1B IL10 IFNG
28
Show member pathways
12.39 TNF IL4 IL1B IL10 IFNG
29
Show member pathways
12.38 TNF IL6 IL23A IL2 IL1B IL10
30
Show member pathways
12.33 TNF IL6 IL4 IL1B IFNG
31 12.25 TNF IL6 IL1B IL10
32 12.24 IL6 HLA-C HLA-B HLA-A
33 12.19 TNF IL6 IL4 IL2 IL1B IFNG
34 12.18 TNF IL6 IL2 IL1B IL10
35 12.17 KIR3DL1 HLA-C HLA-B HLA-A
36 12.17 TNF IL6 IL4 IL2 IL10 IFNG
37
Show member pathways
12.15 IL4 IL2 IL1B IFNG HLA-A
38 12.14 TNFSF11 TNF IL1B IFNG
39 12.14 TNF MMP3 LTA IL6 IL1B
40
Show member pathways
12.14 TNF LTA IL6 IL4 IL2 IL1B
41 12.09 TNF IL6 IL1B IL10 IFNG
42 12.08 TNF MMP3 IL6 IL4 IL23A IL1B
43 12.05 TNFSF11 TNF LTA IL1B
44 12.05 TNFSF11 TNF MMP3 IL6 IL23A IL1B
45
Show member pathways
12.03 IL6 IL4 IL23A IL1B IL17F IL17A
46 12.02 TNF IL6 IL4 IL1B
47
Show member pathways
11.99 IL6 IL23A IL17F IL17A
48 11.94 IL6 IL4 IL2 IFNG
49 11.94 TNF IL6 IL23A IL1B IL10
50
Show member pathways
11.94 TNF LTA IL6 IL2 IL1B IL17F

GO Terms for Spondyloarthropathy

Cellular components related to Spondyloarthropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 TNFSF11 TNF MMP3 LTA IL6 IL4
2 recycling endosome membrane GO:0055038 9.58 HLA-C HLA-B HLA-A
3 phagocytic vesicle membrane GO:0030670 9.54 HLA-C HLA-B HLA-A
4 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-C HLA-B HLA-A
5 extracellular space GO:0005615 9.44 TNFSF11 TNF MMP3 LTA IL6 IL4
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.43 HLA-C HLA-B HLA-A
7 MHC class I protein complex GO:0042612 9.33 HLA-C HLA-B HLA-A

Biological processes related to Spondyloarthropathy according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.21 TNFSF11 TNF IL6 IL4 IL23A IL2
2 adaptive immune response GO:0002250 10.14 IL2 IFNG HLA-C HLA-B HLA-A
3 positive regulation of gene expression GO:0010628 10.13 TNFSF11 TNF IL6 IL4 IL1B IFNG
4 inflammatory response GO:0006954 10.1 TNF IL6 IL23A IL1B IL17F IL17A
5 cell-cell signaling GO:0007267 10.05 LTA IL2 IL1B IL17A
6 positive regulation of protein phosphorylation GO:0001934 10.03 TNF IL2 IL1B IFNG
7 regulation of immune response GO:0050776 10.03 KIR3DL1 IL4 HLA-C HLA-B HLA-A
8 cellular response to lipopolysaccharide GO:0071222 10.02 TNF IL6 IL1B IL10
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 TNFSF11 TNF IL6 IL1B
10 defense response to Gram-positive bacterium GO:0050830 9.96 TNF LTA IL6 HLA-A
11 positive regulation of JNK cascade GO:0046330 9.93 TNFSF11 TNF IL1B
12 positive regulation of DNA-binding transcription factor activity GO:0051091 9.93 TNFSF11 TNF IL6 IL1B IL10
13 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.92 HLA-C HLA-B HLA-A
14 regulation of insulin secretion GO:0050796 9.92 TNF IL1B IFNG
15 positive regulation of inflammatory response GO:0050729 9.92 TNF IL23A IL2 IL1B IFNG
16 response to glucocorticoid GO:0051384 9.91 TNF IL6 IL10
17 type I interferon signaling pathway GO:0060337 9.91 HLA-C HLA-B HLA-A
18 interferon-gamma-mediated signaling pathway GO:0060333 9.91 IFNG HLA-C HLA-B HLA-A
19 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.9 TNF IL23A IL1B
20 positive regulation of interleukin-6 production GO:0032755 9.9 TNF IL6 IL1B
21 positive regulation of protein complex assembly GO:0031334 9.9 TNF MMP3 IFNG
22 humoral immune response GO:0006959 9.89 TNF LTA IL6 IFNG
23 positive regulation of phagocytosis GO:0050766 9.87 TNF IL1B IFNG
24 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 TNF IL1B IFNG
25 antigen processing and presentation GO:0019882 9.86 HLA-C HLA-B HLA-A
26 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.85 IL4 IL2 IL1B
27 positive regulation of cytokine secretion GO:0050715 9.85 TNF IL10 IFNG
28 positive regulation of JAK-STAT cascade GO:0046427 9.85 TNF IL6 IL10
29 microglial cell activation GO:0001774 9.84 TNF IL4 IFNG
30 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.84 HLA-C HLA-B HLA-A
31 negative regulation of neurogenesis GO:0050768 9.83 TNF IL6 IL1B
32 positive regulation of T cell proliferation GO:0042102 9.83 IL6 IL4 IL23A IL2 IL1B
33 positive regulation of T cell mediated cytotoxicity GO:0001916 9.82 IL23A HLA-B HLA-A
34 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.8 TNF IL6 IL17F IL17A
35 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 TNF IL6 IL4 IL23A IL2 IFNG
36 astrocyte activation GO:0048143 9.79 TNF IL1B IFNG
37 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.78 TNF IL1B IFNG
38 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.77 TNF IL1B IL10
39 positive regulation of interleukin-6 secretion GO:2000778 9.77 TNF IL1B IL17F IL17A IFNG
40 positive regulation of neuroinflammatory response GO:0150078 9.76 TNF IL6 IL1B
41 positive regulation of glial cell proliferation GO:0060252 9.76 TNF LTA IL6 IL1B
42 regulation of neuroinflammatory response GO:0150077 9.75 MMP3 IL6
43 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.75 IL4 IL10
44 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.75 IL23A IL1B
45 negative regulation of amyloid-beta clearance GO:1900222 9.75 TNF IFNG
46 positive regulation of isotype switching to IgG isotypes GO:0048304 9.75 IL4 IL2
47 positive regulation of MHC class II biosynthetic process GO:0045348 9.75 IL4 IL10 IFNG
48 negative regulation of lipid storage GO:0010888 9.74 TNF IL6
49 negative regulation of T-helper 17 cell differentiation GO:2000320 9.74 IL4 IL2
50 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.74 TNF IL17A IFNG

Molecular functions related to Spondyloarthropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 TNFSF11 TNF MMP3 LTA KIR3DL1 IL6
2 growth factor activity GO:0008083 9.62 IL6 IL4 IL2 IL10
3 peptide antigen binding GO:0042605 9.43 HLA-C HLA-B HLA-A
4 cytokine activity GO:0005125 9.4 TNFSF11 TNF LTA IL6 IL4 IL23A
5 tumor necrosis factor receptor binding GO:0005164 9.33 TNFSF11 TNF LTA
6 TAP binding GO:0046977 9.13 HLA-C HLA-B HLA-A

Sources for Spondyloarthropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....